Answers are grounded in this paper and cite their sources.
transplantation, the appeal is concrete: donor scarcity, ischaemia-reperfusion injury and posttransplant complications remain inadequately addressed by available models, and human organoid systems now offer a tractable middle ground between cell lines and animal experimentation. We previously outlined an agenda for bringing organoid technology and organ transplantation into closer dialogue (4). The contributions assembled in this Special Issue make clear how far that convergence has come, and what remains to be done.What gives organoids their traction in transplant research is the combination of human cellular identity, three-dimensional architecture, and increasingly tractable manipulation through bioengineering (5). These properties allow organoids to recapitulate developmental programmes, injury responses, and host-graft interactions in human tissue, and to do so with sufficient fidelity that organoid readouts can be compared directly against paired clinical specimens. Work over the past several years has also established that incorporating supporting cell types into composite organoids can improve viability, vascularisation, and engraftment after transplantation, providing a design principle that now informs cell-replacement strategies across organ systems (6)(7)(8).The five papers in this issue articulate a shared trajectory: organoids are no longer being deployed merely as in vitro proxies for transplantation, but as entities prepared for it. Shankar et al. address one of the most central questions for organoid transplantation: how human organoid tissue interacts with the immune system. Using human iPSC-derived kidney organoids exposed to peripheral blood mononuclear cells in vitro and after implantation in immune-deficient mice followed by human immune-cell transfer, the authors show that organoids are not immunologically inert. They undergo infiltration by T cells and macrophages, with stromal activation, induction of immune-response genes, epithelial PD-L1 expression, fibrosis-associated changes, and reduced expression of nephron differentiation and functional markers. This work provides an important platform for modelling alloimmune injury in human kidney-like tissue and emphasizes that immunogenicity must be integrated early into organoid translation.Two papers focus on biliary complications after liver transplantation, a persistent clinical problem and a highly relevant test case for organoid-based modelling. Rejas and Junger provide a comprehensive review of cholangiocyte organoids in liver transplantation, highlighting their capacity to model cholangiopathies, ischemia-reperfusion injury, primary sclerosing cholangitis, primary biliary cholangitis, and genetic biliary disease. The review is particularly valuable in connecting organoid plasticity with clinically meaningful regeneration, including the possibility of using cholangiocyte organoids to repair injured bile ducts, support personalized medicine, and eventually reduce the burden of post-transplant cholangiopathy. Their findings suggest that normothermic perfusion achieves broader and more efficient kidney targeting than local injection. In rat transplantation models, delivered tubuloids persisted, integrated into the host parenchyma, and formed tubular structures with a predominantly proximal phenotype; in a discarded human kidney, perfusion enabled cortical delivery of tubuloids and was associated with lower expression of selected injury and inflammatory markers. Although still preliminary, this work points to ex vivo perfusion as a clinically realistic bridge between organoid biology and graft-directed regenerative therapy.Together, these contributions show that organoids are no longer only "mini-organs" for developmental biology. They are becoming experimental grafts, immune targets, disease avatars, injury sensors, drug-testing platforms, and vehicles for regeneration. The field now faces important challenges: improving maturation, vascularisation, innervation where relevant, scalability, reproducibility, genetic and epigenetic stability, immune compatibility, and regulatory standardisation. Equally important, ethical and societal reflection must accompany the science. The growing use of discarded human organs as preclinical platforms, the prospect of gene-edited or hypoimmune organoid products, and the unequal global access to advanced therapy medicinal products (9) each raise questions that the transplant community cannot leave to others to resolve. This Special Issue captures a field in transition. Organoid technology will not replace transplantation in the immediate future, nor should its current limitations be underestimated.Yet these studies make clear that organoids are already reshaping how we understand graft injury, test interventions, and imagine regenerative solutions for organ failure. Their greatest contribution may be to transform transplantation research from the replacement of damaged organs alone toward the active repair, modelling, and engineering of transplantable tissues.
No takes yet. Share an insight, caveat, or question.
Ekaterine Berishvili (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: